{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T17:21:19Z","timestamp":1770744079003,"version":"3.49.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T00:00:00Z","timestamp":1601251200000},"content-version":"vor","delay-in-days":271,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007075","name":"European Society for Medical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007075","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2020]]},"DOI":"10.1136\/esmoopen-2019-000628","type":"journal-article","created":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T01:25:10Z","timestamp":1585185910000},"page":"e000628","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Current models, challenges and best practices for work conducted between European academic cooperative groups and industry"],"prefix":"10.1016","volume":"5","clinical-trial-number":[{"clinical-trial-number":"nct00045032","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00004067","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00005970","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00021255","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01524978","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00268476","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03088059","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02154490","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Rolf A.","family":"Stahel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Lacombe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatima","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo G.","family":"Casali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastassia","family":"Negrouk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Marais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Hiltbrunner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malvika","family":"Vyas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Varoqueaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claas","family":"Frohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Cornet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Amauri","family":"Soares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nora Drove","family":"Ubreva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Zaiac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur","family":"Cannon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Buechele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marika","family":"Crohns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/esmoopen-2019-000628_bb0010","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000187","article-title":"Safeguarding the future of independent, academic clinical cancer research in Europe for the benefit of patients","volume":"2","author":"Negrouk","year":"2017","journal-title":"ESMO Open"},{"key":"10.1136\/esmoopen-2019-000628_bb0015","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1158\/1078-0432.CCR-10-1273","article-title":"Phase III clinical trial development: a process of chutes and ladders","volume":"16","author":"Dilts","year":"2010","journal-title":"Clin. Cancer Res"},{"key":"10.1136\/esmoopen-2019-000628_bb0020","author":"The European Parliament and the Council of the European Union","year":"2014","journal-title":"Regulation (EU) NO 536\/2014 of the European Parliament and of the Council 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001\/20\/EC"},{"key":"10.1136\/esmoopen-2019-000628_bb0025","doi-asserted-by":"crossref","DOI":"10.1038\/nrd.2017.218","article-title":"Steps forward for cancer precision medicine","volume":"17","author":"Salgado","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1136\/esmoopen-2019-000628_bb0030","unstructured":"EUR-Lex. EUR-Lex - 32016R0679 - EN. Available: https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=celex%3A32016R0679"},{"key":"10.1136\/esmoopen-2019-000628_bb0035","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S1470-2045(18)30620-X","article-title":"Does GDPR harm or benefit research participants? an EORTC point of view","volume":"19","author":"Negrouk","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1136\/esmoopen-2019-000628_bb0040","doi-asserted-by":"crossref","first-page":"493","DOI":"10.4155\/cli.11.23","article-title":"International investigator-driven clinical trials: challenges and opportunities for US\u2013Europe cooperation through the US cooperative group networks","volume":"1","author":"Lacombe","year":"2011","journal-title":"Clin Investig"},{"key":"10.1136\/esmoopen-2019-000628_bb0045","unstructured":"Forte. What\u2019s Fair about Fair Market Value in Research? Available: https:\/\/forteresearch.com\/news\/whats-fair-about-fair-market-value-in-research\/"},{"key":"10.1136\/esmoopen-2019-000628_bb0050","unstructured":"EORTC. GSK hands over large tumour sample collection in exciting new collaboration. Available: https:\/\/www.eortc.org\/blog\/2018\/10\/04\/gsk-hands-over-large-tumour-sample-collection-in-exciting-new-collaboration\/"},{"key":"10.1136\/esmoopen-2019-000628_bb0055","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1097\/IGC.0000000000000478","article-title":"European Network of Gynaecological Oncological Trial Groups' Requirements for Trials Between Academic Groups and Industry Partners--First Update 2015","volume":"25","author":"du Bois","year":"2015","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/esmoopen-2019-000628_bb0060","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1200\/JCO.2006.07.8956","article-title":"European perspective on the costs and cost-effectiveness of cancer therapies","volume":"25","author":"Drummond","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2019-000628_bb0065","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1016\/j.ejca.2013.05.016","article-title":"How can innovative forms of clinical research contribute to deliver affordable cancer care in an evolving health care environment?","volume":"49","author":"Burock","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1136\/esmoopen-2019-000628_bb0070","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.healthpol.2014.08.004","article-title":"Analysis of endpoints used in marketing authorisations versus value assessments of oncology medicines in Germany","volume":"118","author":"Ruof","year":"2014","journal-title":"Health Policy"},{"key":"10.1136\/esmoopen-2019-000628_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021030","article-title":"Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials","volume":"6","author":"Yin","year":"2011","journal-title":"PLoS One"},{"key":"10.1136\/esmoopen-2019-000628_bb0080","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000628_bb0085","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000628_bb0090","doi-asserted-by":"crossref","first-page":"6129","DOI":"10.1200\/JCO.2009.23.0946","article-title":"Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial","volume":"27","author":"Spielmann","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2019-000628_bb0095","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1200\/JCO.2011.36.7045","article-title":"Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer","volume":"29","author":"Perez","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2019-000628_bb0100","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa053028","article-title":"Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer","volume":"354","author":"Joensuu","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000628_bb0105","article-title":"Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC\u2192T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC\u2192TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive ea","author":"Slamon","year":"2009"},{"key":"10.1136\/esmoopen-2019-000628_bb0110","first-page":"LBA5","article-title":"Subcutaneous injection of trastuzumab - analysis of administration time and injection site reactions","volume":"2012","author":"Pivot","year":"2012","journal-title":"ESMO"},{"key":"10.1136\/esmoopen-2019-000628_bb0115","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","article-title":"11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the Herceptin adjuvant (HERA) trial","volume":"389","author":"Cameron","year":"2017","journal-title":"Lancet"},{"key":"10.1136\/esmoopen-2019-000628_bb0120","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1703643","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer","volume":"377","author":"von Minckwitz","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000628_bb0125","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000628_bb0130","unstructured":"STAMPEDE. Available: http:\/\/www.stampedetrial.org\/"},{"key":"10.1136\/esmoopen-2019-000628_bb0135","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"The Lancet"},{"key":"10.1136\/esmoopen-2019-000628_bb0140","unstructured":"IMI Project Factsheets. Available: http:\/\/www.imi.europa.eu\/projects-results\/project-factsheets"},{"key":"10.1136\/esmoopen-2019-000628_bb0145","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1001\/jamaoncol.2015.6326","article-title":"Genetic basis for PD-L1 expression in squamous cell carcinomas of the cervix and vulva","volume":"2","author":"Howitt","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1136\/esmoopen-2019-000628_bb0150","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1158\/2326-6066.CIR-16-0072","article-title":"The intratumoral balance between metabolic and immunologic gene expression is associated with anti-PD-1 response in patients with renal cell carcinoma","volume":"4","author":"Ascierto","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1136\/esmoopen-2019-000628_bb0155","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10391","article-title":"Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis","volume":"7","author":"Dubin","year":"2016","journal-title":"Nat Commun"},{"key":"10.1136\/esmoopen-2019-000628_bb0160","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1158\/1078-0432.CCR-15-1535","article-title":"Combination therapy with anti-PD-1, Anti-TIM-3, and focal radiation results in regression of murine gliomas","volume":"23","author":"Kim","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1136\/esmoopen-2019-000628_bb0165","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1158\/2326-6066.CIR-16-0022","article-title":"Interferon-\u03b3 Production by Peripheral Lymphocytes Predicts Survival of Tumor-Bearing Mice Receiving Dual PD-1\/CTLA-4 Blockade","volume":"4","author":"McNamara","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1136\/esmoopen-2019-000628_bb0170","unstructured":"Lung-MAP. Lung cancer master protocol|. Available: https:\/\/www.lung-map.org\/about-lung-map"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920300569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920300569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/esmoopen-2019-000628","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:24:14Z","timestamp":1761855854000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702920300569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"alternative-id":["S2059702920300569"],"URL":"https:\/\/doi.org\/10.1136\/esmoopen-2019-000628","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current models, challenges and best practices for work conducted between European academic cooperative groups and industry","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/esmoopen-2019-000628","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 THE AUTHORS. Published by Elsevier Limited on behalf of European Society for Medical Oncology; Originally published by BMJ.","name":"copyright","label":"Copyright"}],"article-number":"e000628"}}